USA - NASDAQ:BLFS - US09062W2044 - Common Stock
The current stock price of BLFS is 25.92 USD. In the past month the price decreased by -9.84%. In the past year, price increased by 23.31%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.25 | 222.04B | ||
| DHR | DANAHER CORP | 28.46 | 157.10B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 167.64 | 50.87B | ||
| A | AGILENT TECHNOLOGIES INC | 27.8 | 42.96B | ||
| IQV | IQVIA HOLDINGS INC | 18.99 | 37.55B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.6 | 29.82B | ||
| WAT | WATERS CORP | 30.5 | 23.06B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.73 | 19.69B | ||
| ILMN | ILLUMINA INC | 27.98 | 18.75B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.79 | 16.79B | ||
| TEM | TEMPUS AI INC | N/A | 12.35B | ||
| RVTY | REVVITY INC | 19.65 | 10.93B |
BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. The company is headquartered in Bothell, Washington and currently employs 159 full-time employees. The firm facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
BIOLIFE SOLUTIONS INC
Suite 310, 3303 Monte Villa Parkway
Bothell WASHINGTON 98021 US
CEO: Michael Rice
Employees: 159
Phone: 14254011400
BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. The company is headquartered in Bothell, Washington and currently employs 159 full-time employees. The firm facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
The current stock price of BLFS is 25.92 USD. The price decreased by -0.46% in the last trading session.
BLFS does not pay a dividend.
BLFS has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
BIOLIFE SOLUTIONS INC (BLFS) operates in the Health Care sector and the Life Sciences Tools & Services industry.
The Revenue of BIOLIFE SOLUTIONS INC (BLFS) is expected to decline by -5.39% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ChartMill assigns a technical rating of 4 / 10 to BLFS. When comparing the yearly performance of all stocks, BLFS is one of the better performing stocks in the market, outperforming 76.68% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to BLFS. BLFS has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months BLFS reported a non-GAAP Earnings per Share(EPS) of 0.25. The EPS increased by 123.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.82% | ||
| ROE | -0.91% | ||
| Debt/Equity | 0 |
16 analysts have analysed BLFS and the average price target is 31.93 USD. This implies a price increase of 23.17% is expected in the next year compared to the current price of 25.92.
For the next year, analysts expect an EPS growth of 28% and a revenue growth -5.39% for BLFS